Dakota Access Pipeline: Authorities start removing protesters - more >>


Ranbaxy Pharmaceuticals recalls batches of generic Lipitor pills

Doses may contain small glass particles

Ranbaxy recalls generic Lipitor doses

UNDATED (AP) _ Ranbaxy Pharmaceuticals is recalling several doses of its generic version of Lipitor because some batches of the cholesterol fighter may contain small glass particles.

The generic drugmaker's website says it is recalling 10-, 20- and 40-milligram doses of atorvastatin calcium tablets. The recall is tied to certain lot numbers of the drug. It is not tied to an 80-milligram version of the tablets.

Patients can call the pharmacy where they filled their prescriptions if they are not sure about whether their prescription came from one of the recalled lot numbers.

Ranbaxy Pharmaceuticals is a subsidiary of Indian drugmaker Ranbaxy Laboratories Ltd. The company said in a regulatory filing with the Bombay Stock Exchange its investigation into the recall will be completed within two weeks.

Lipitor, long the world's top-selling drug, lost U.S. patent protection nearly a year ago. Ranbaxy began selling its generic version of the drug last December, as did Watson Pharmaceuticals Inc., which made a version authorized by Pfizer. Several more generic versions of the drug then hit the market last May.

A full list of recalled lots is available here.

Due to our site relaunch on October 25, previous comments on existing stories are no longer available.  This change is due to the limitations of Facebook's software 

The views expressed are not those of this company or its affiliated companies. Please note by clicking on "Post" you acknowledge that you have read the TERMS OF USE  and the comment you are posting is in compliance with such terms. Your comments may be used on air. Be polite. Inappropriate posts or posts containing offsite links may be removed by the moderator.


There is 1 area under advisories, watches or warnings.   DETAILS >>>

Allentown, PA 18102





  • %

This Week's Circulars

Top Stories

Latest from the newsroom

More from the Newsroom